Trial Profile
SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Acronyms SAINT
- 16 May 2023 Planned End Date changed from 31 Mar 2023 to 31 Mar 2024.
- 16 May 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 13 Sep 2022 Results (n=101) presented at the 47th European Society for Medical Oncology Congress.